Showing results (81-90 of 125) with videos related to

Sort By:
Pageof 13
Frontiers in Oncology|November 22, 2021
First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 StudySonia Pernas, Patricia Villagrasa, Ana Vivancos, et al.
The Lancet. Oncology|November 25, 2015
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trialJavier Cortés, Véronique Dieras, Jungsil Ro, et al.
NPJ Breast Cancer|March 6, 2024
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapyTomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal, et al.
Cancer Treatment Reviews|December 22, 2024
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysisFrancesco Schettini, Sabrina Nucera, Tomás Pascual, et al.
Molecular Oncology|May 29, 2021
Gene expression profiles of breast cancer metastasis according to organ siteFara Brasó-Maristany, Laia Paré, Nuria Chic, et al.
NPJ Precision Oncology|November 7, 2025
Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterationsNoelia Martinez-Jañez, José Ángel García-Saenz, Sonia Pernas, et al.
Breast Cancer Research : BCR|August 4, 2023
miR-203 drives breast cancer cell differentiationNuria G Martínez-Illescas, Silvia Leal, Patricia González, et al.
The Lancet. Oncology|December 11, 2017
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trialAngelo Di Leo, Stephen Johnston, Keun Seok Lee, et al.
Ebiomedicine|June 23, 2021
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapyNuria Chic, Francesco Schettini, Fara Brasó-Maristany, et al.
Nature Medicine|September 13, 2024
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trialNadia Harbeck, Eva Ciruelos, Guy Jerusalem, et al.
Pageof 13